Investigational Drug Details
| Drug ID: | D231 |
| Drug Name: | MN-001 |
| Synonyms: | Tipelukast |
| Type: | Chemical drug |
| DrugBank ID: | DB12435 |
| DrugBank Description: | Tipelukast is under investigation for the treatment of IPF and Idiopathic pulmonary fibrosis. |
| PubChem ID: | 9893228 |
| CasNo: | 125961-82-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(CC)c1c(OCCCC(=O)O)c(C(=O)C)ccc1OCCCSc1c(CCC)c(O)c(cc1)C(=O)C |
| Structure: |
|
| InChiKey: | KPWYNAGOBXLMSE-UHFFFAOYSA-N |
| Molecular Weight: | 530.683 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT02681055) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0140 | NCT02681055 | Phase 2 | Completed | No Results Available | March 2016 | October 22, 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title |
|---|